Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Overview
Nutriband Inc is a Florida-based pharmaceutical company specializing in the development of transdermal drug delivery systems that incorporate advanced abuse-deterrent technologies. Its core business revolves around transdermal pharmaceutical products engineered to mitigate the risks of drug abuse, misuse, diversion, and accidental exposure, with a special emphasis on addressing the global opioid crisis. Utilizing proprietary technology that integrates aversive agents into transdermal patches, Nutriband is dedicated to improving patient safety while ensuring essential medications remain accessible for those in need.
Advanced Abuse-Deterrent Technology
The company’s flagship innovation, AVERSA technology, is designed to deter the oral abuse of potent drugs by utilizing taste aversion methods. This technology can be incorporated into various transdermal patches, a critical step toward preventing accidental exposures—particularly in vulnerable populations such as young children. The patented approach provides an additional safeguard by making the potential for abuse less appealing, thereby enhancing the overall safety profile of drugs with abuse potential.
Business Model and Operations
Nutriband Inc generates revenue primarily through the sale of consumer transdermal and coated products, as well as through contract manufacturing services provided by its wholly owned subsidiary, Pocono Pharma. The company leverages its strategic partnerships with top industry players to extend its market reach, including engagements with major retailers and established pharmaceutical manufacturing organizations. This diversified revenue approach not only supports the current portfolio but also positions Nutriband as a flexible partner in both the healthcare and contract manufacturing sectors.
Strategic Partnerships and Intellectual Property
A cornerstone of Nutriband’s success is its robust global intellectual property portfolio, which spans across more than 40 countries including the United States, Europe, Japan, and Australia. Such extensive protection underpins its innovative AVERSA technology and provides a competitive edge in the increasingly critical field of abuse-deterrent transdermal systems. Strategic alliances with industry experts such as Kindeva Drug Delivery further reinforce its position by ensuring that large-scale manufacturing processes align with FDA guidelines and international industry standards.
Market Position and Industry Significance
Operating at the nexus of pharmaceutical innovation and patient safety, Nutriband Inc is positioned distinctively in the competitive landscape of transdermal drug delivery systems. Its strategic focus on developing abuse-deterrent products addresses a significant unmet need in the market, particularly in the context of managing opioid-related risks without compromising therapeutic access. Through its commitment to evolving industry standards and enhancing product safety, Nutriband has established itself as a forward-thinking entity within a critical market segment.
Product Portfolio and Future Applications
While its lead product, an abuse-deterrent fentanyl patch, remains at the forefront of its development efforts, Nutriband is actively expanding its portfolio to include additional transdermal therapies. By integrating its core AVERSA technology across multiple product lines, the company aims to address a wide spectrum of medications with abuse potential, including opioids and stimulants. This strategy not only diversifies its technology applications but also solidifies its reputation as an innovator in transdermal pharmaceutical solutions.
Commitment to Safety and Regulatory Compliance
At the heart of Nutriband’s mission is a dedication to enhancing patient safety through rigorous research, development, and close adherence to regulatory standards. The company emphasizes clear, methodical approaches that streamline market entry while upholding the highest safety measures. This balance of innovation and compliance is critical in a market where the prevention of misuse and accidental exposure is of paramount concern.
Overall, Nutriband Inc exemplifies a strategic blend of innovative product development, methodical market expansion, and a steadfast commitment to patient safety. Its robust technology platform, significant IP portfolio, and established industry partnerships underscore its role as a key contributor to the evolution of abuse-deterrent pharmaceutical products.
Nutriband (NASDAQ: NTRB) has secured a Certificate of Registration from the USPTO for trademark registration Number 7,692,920 on February 18, 2025. The trademark covers product research and development, scientific research and development, biochemical research and development, and pharmaceutical research and development under Class 042.
The Nutriband™ trademark is important for commercializing the company's AVERSA platform technology, designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential in transdermal patches. The company's leading product, AVERSA™ Fentanyl, is being developed in partnership with Kindeva Drug Delivery, focusing on scaling up commercial manufacturing before FDA submission. Market analysis by Health Advances projects potential peak annual U.S. sales of $80-200 million for AVERSA™ Fentanyl.
Nutriband Inc. (NASDAQ:NTRB) has formalized an exclusive development partnership with Kindeva Drug Delivery for Aversa™ Fentanyl, an abuse-deterrent fentanyl patch. The partnership involves shared development costs in exchange for milestone payments. The product combines Nutriband's Aversa™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch.
The Aversa™ technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The technology is protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China. If successful, Aversa Fentanyl would become the world's first abuse-deterrent opioid patch, with potential peak annual US sales ranging from $80 million to $200 million.
Nutriband Inc. (NASDAQ: NTRB) has announced the appointment of World and European Wrestling Gold medalist and Olympic Silver medalist Anastasia Nichita to its Product Advisory Board. The appointment aims to expand the Nutriband Brand and promote its over-the-counter sports and consumer products internationally.
The company, which develops transdermal pharmaceutical products through its subsidiary Pocono Pharma, produces multiple products including AI Tape. This product combines traditional kinesiology tape benefits with soothing and therapeutic ingredients in a proprietary adhesive mix.
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Allowance from the USPTO for patent application 18/369,241, covering its Aversa™ abuse deterrent technology. This technology is designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential in transdermal patches.
The company's lead product, Aversa™ Fentanyl, aims to become the first abuse-deterrent fentanyl transdermal system. The technology utilizes a proprietary aversive agent coating that employs taste aversion to deter oral abuse. The intellectual property is protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China.
According to a market analysis report, Aversa Fentanyl has the potential to achieve peak annual US sales between $80 million to $200 million.
Nutriband (NASDAQ: NTRB) has released its 2024 shareholder letter highlighting significant achievements and 2025 outlook. The company reported record Q3 revenue of $645,796, a 51% year-over-year increase. Key developments include advancing their AVERSA™ Fentanyl product, projected to achieve peak annual U.S. sales of $80-200 million, toward commercialization with partner Kindeva Drug Delivery.
The company secured patent approvals in China and Hong Kong, expanding their intellectual property portfolio to 46 countries. Nutriband raised $8.4 million through a private placement and established an exclusive supplier agreement with Fit For Life Group for major fitness brands. The company plans to submit the New Drug Application (NDA) for AVERSA™ Fentanyl in 2025, with potential regulatory approval expected by year-end.
Nutriband Inc. (NASDAQ:NTRB) has extended its Chinese patent to Macao for its AVERSA™ abuse-deterrent transdermal technology, bringing the total patent coverage to 46 countries and territories. The Macao IP Office assigned patent number J/9010, effective December 17, 2024.
The AVERSA™ technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband is collaborating with Kindeva Drug Delivery to develop AVERSA™ Fentanyl, targeting FDA approval in the first half of 2025. The product has potential peak annual US sales of $80-200 million and aims to be the world's first abuse-deterrent opioid patch.
Nutriband Inc. (NASDAQ:NTRB) reported strong Q3 2024 financial results, with record revenue of $645,796, up 50.94% year-over-year. The company maintains a solid cash position of $5.7 million, with total assets of $12.55 million and stockholders' equity of $11.23 million.
Through its Pocono Pharma subsidiary, Nutriband is expanding its kinesiology tape manufacturing services, with products available in major retailers like Target, Walmart, Walgreens, and CVS. The company continues to progress with AVERSA Fentanyl development, targeting NDA submission in first half of 2025, requiring only a single phase 1 Human Abuse Potential study.
Market analysis projects potential peak annual sales of $80-$200 million for AVERSA Fentanyl and up to $130 million for AVERSA Buprenorphine.
Nutriband Inc. (Nasdaq: NTRB) has announced its participation in the Noble Conference at Florida Atlantic University in Boca Raton on December 3rd-4th, 2024. Company President and Chairman Serguei Melnik will present on December 4th at 1:30 PM in Conference Room 3, focusing on the company's AVERSA technology.
The company specializes in developing transdermal pharmaceutical products, with their flagship product being an abuse-deterrent fentanyl patch incorporating AVERSA™ technology. This innovative technology can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Presentation details and replay will be available on Channelchek and Youtube after the conference.
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Publication for its Hong Kong patent protecting AVERSA™ abuse-deterrent transdermal technology. The patent, assigned Publication Number 40085268 B, will be published on December 20, 2024. AVERSA™ technology is now protected by patents in 46 countries, including major markets. The technology incorporates aversive agents into transdermal patches to prevent abuse of drugs like opioids and stimulants. Nutriband is developing AVERSA™ Fentanyl with Kindeva Drug Delivery, potentially becoming the world's first abuse-deterrent opioid patch with projected annual US sales of $80-200 million.
Nutriband (NASDAQ:NTRB) has received full patent issuance from the Chinese National Intellectual Property Administrant (CNIPA) for its 'Abuse and Misuse Deterrent Transdermal System.' The patent (No: ZL 202211158031) supports the company's AVERSA™ technology, developed by 4p Therapeutics, which incorporates taste aversion to prevent abuse of opioid-based transdermal patches. This follows CNIPA's notice of allowance issued in September 2024.
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
What is Nutriband Inc's core business?
How does the AVERSA technology work?
What are the key revenue streams for Nutriband Inc?
How does Nutriband position itself within the pharmaceutical industry?
What strategic partnerships support Nutriband's operations?
In which markets are Nutriband's products available?
How is Nutriband addressing the opioid crisis?
How does Nutriband protect its innovative technology?
